Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=53286888&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20150363(A)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/NZ2014/000001external-prioritypatent/WO2014120021A1/en
Application filed by Aft Pharmaceuticals LtdfiledCriticalAft Pharmaceuticals Ltd
Publication of CR20150363ApublicationCriticalpatent/CR20150363A/en
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
El uso del hidrocloruro de fenilefrina (o una cantidad equivalente de una forma alternativa farmacéuticamente aceptable de fenilefrina) y paracetamol en la producción de un medicamento combinado para el tratamiento de la congestión de las mucosas de las vías respiratorias superiores, medicamento que comprende la combinación de tales sustancias con excipientes.The use of phenylephrine hydrochloride (or an equivalent amount of a pharmaceutically acceptable alternative form of phenylephrine) and paracetamol in the production of a combination medication for the treatment of congestion of the mucous membranes of the upper respiratory tract, a drug comprising the combination of such substances with excipients.
CR20150363A2013-02-042015-07-09
COMBINATION OF A MEDICINAL PRODUCT THAT INCLUDES PHENYLEFRINE AND PARACETAMOL
CR20150363A
(en)
Use of an amount of laquinimod, which is used to prepare a medication to treat a human patient affected with multiple sclerosis or who has a clinically isolated syndrome; a package, an amount of laquinimod and a pharmaceutical composition thereof.
Use of pidotimod or its stereoisomers and / or physiologically acceptable salts to prepare a medicament useful in the treatment of diseases associated with inflammation, where there is aberrant hyperactivation of the non-canonical nfkb pathway.